Cerebrospinal fluid CXCL13 identifies a subgroup of people living with HIV with prominent intrathecal synthesis, immune activation, and neurocognitive impairment regardless of effective antiretroviral therapy

Mattia Trunfio, Lorenzo Mighetto, Laura Napoli, Cristiana Atzori, Marco Nigra, Giulia Guastamacchia, Stefano Bonora, Giovanni Di Perri, Andrea Calcagno
doi: https://doi.org/10.1101/2022.12.13.22283427

Article usage

Article usage: December 2022 to January 2025

AbstractFullPdf
Dec 20223251434
Jan 202355814
Feb 20233728
Mar 20233014
Apr 20232716
May 20231313
Jun 20231343
Jul 2023712
Aug 202317125
Sep 20231656
Oct 2023940
Nov 20231662
Dec 2023701
Jan 2024803
Feb 20241525
Mar 20241504
Apr 20241059
May 2024424
Jun 2024533
Jul 2024378
Aug 2024614
Sep 2024834
Oct 2024713
Nov 202415159
Dec 20243222
Jan 2025210
Back to top
Posted December 14, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Cerebrospinal fluid CXCL13 identifies a subgroup of people living with HIV with prominent intrathecal synthesis, immune activation, and neurocognitive impairment regardless of effective antiretroviral therapy
Mattia Trunfio, Lorenzo Mighetto, Laura Napoli, Cristiana Atzori, Marco Nigra, Giulia Guastamacchia, Stefano Bonora, Giovanni Di Perri, Andrea Calcagno
medRxiv 2022.12.13.22283427; doi: https://doi.org/10.1101/2022.12.13.22283427
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area